IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v51y2000i3p135-147.html
   My bibliography  Save this article

Diabetes nephropathy in the Netherlands: a cost effectiveness analysis of national clinical guidelines

Author

Listed:
  • van Os, Nicole
  • Niessen, Louis W.
  • Bilo, Henk J. G.
  • Casparie, Anton F.
  • van Hout, Ben A.

Abstract

No abstract is available for this item.

Suggested Citation

  • van Os, Nicole & Niessen, Louis W. & Bilo, Henk J. G. & Casparie, Anton F. & van Hout, Ben A., 2000. "Diabetes nephropathy in the Netherlands: a cost effectiveness analysis of national clinical guidelines," Health Policy, Elsevier, vol. 51(3), pages 135-147, April.
    • Handle: RePEc:eee:hepoli:v:51:y:2000:i:3:p:135-147
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168-8510(00)00063-4
    Download Restriction: Full text for ScienceDirect subscribers only
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Martin J. Buxton & Michael F. Drummond & Ben A. Van Hout & Richard L. Prince & Trevor A. Sheldon & Thomas Szucs & Muriel Vray, 1997. "Modelling in Ecomomic Evaluation: An Unavoidable Fact of Life," Health Economics, John Wiley & Sons, Ltd., vol. 6(3), pages 217-227, May.
    2. Mason, James & Eccles, Martin & Freemantle, Nick & Drummond, Michael, 1999. "A framework for incorporating cost-effectiveness in evidence-based clinical practice guidelines," Health Policy, Elsevier, vol. 47(1), pages 37-52, April.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Charles Christian Adarkwah & Afschin Gandjour & Maren Akkerman & Silvia M Evers, 2011. "Cost-Effectiveness of Angiotensin-Converting Enzyme Inhibitors for the Prevention of Diabetic Nephropathy in The Netherlands – A Markov Model," PLOS ONE, Public Library of Science, vol. 6(10), pages 1-10, October.
    2. Cornelis Boersma & Jarir Atthobari & Ron Gansevoort & Lolkje Jong-Van den Berg & Paul Jong & Dick Zeeuw & Lieven Annemans & Maarten Postma, 2006. "Pharmacoeconomics of Angiotensin II Antagonists in Type 2 Diabetic Patients with Nephropathy," PharmacoEconomics, Springer, vol. 24(6), pages 523-535, June.
    3. Alexander V van Schoonhoven & Judith J Gout-Zwart & Marijke J S de Vries & Antoinette D I van Asselt & Evgeni Dvortsin & Pepijn Vemer & Job F M van Boven & Maarten J Postma, 2019. "Costs of clinical events in type 2 diabetes mellitus patients in the Netherlands: A systematic review," PLOS ONE, Public Library of Science, vol. 14(9), pages 1-22, September.
    4. Polak, B. C. P. & Crijns, H. & Casparie, A. F. & Niessen, L. W., 2003. "Cost-effectiveness of glycemic control and ophthalmological care in diabetic retinopathy," Health Policy, Elsevier, vol. 64(1), pages 89-97, April.
    5. Mark Knezevic, 2006. "Estimating the Long-Term Costs of Diabetic Kidney Disease: an Economic Approach," Economics Discussion / Working Papers 06-06, The University of Western Australia, Department of Economics.
    6. Daniel M. Sugrue & Thomas Ward & Sukhvir Rai & Phil McEwan & Heleen G. M. Haalen, 2019. "Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design," PharmacoEconomics, Springer, vol. 37(12), pages 1451-1468, December.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Joseph F. Levy & Marjorie A. Rosenberg, 2019. "A Latent Class Approach to Modeling Trajectories of Health Care Cost in Pediatric Cystic Fibrosis," Medical Decision Making, , vol. 39(5), pages 593-604, July.
    2. Hossein Haji Ali Afzali & Jonathan Karnon & Jodi Gray, 2012. "A proposed model for economic evaluations of major depressive disorder," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(4), pages 501-510, August.
    3. Huajie Jin & Paul Tappenden & Stewart Robinson & Evanthia Achilla & David Aceituno & Sarah Byford, 2020. "Systematic review of the methods of health economic models assessing antipsychotic medication for schizophrenia," PLOS ONE, Public Library of Science, vol. 15(7), pages 1-18, July.
    4. John Hutton, 2012. "‘Health Economics’ and the evolution of economic evaluation of health technologies," Health Economics, John Wiley & Sons, Ltd., vol. 21(1), pages 13-18, January.
    5. Cleemput, Irina & Kesteloot, Katrien & DeGeest, Sabina, 2002. "A review of the literature on the economics of noncompliance. Room for methodological improvement," Health Policy, Elsevier, vol. 59(1), pages 65-94, January.
    6. Nicholas Graves & Adrian G Barnett & Kate A Halton & Jacob L Veerman & Elisabeth Winkler & Neville Owen & Marina M Reeves & Alison Marshall & Elizabeth Eakin, 2009. "Cost-Effectiveness of a Telephone-Delivered Intervention for Physical Activity and Diet," PLOS ONE, Public Library of Science, vol. 4(9), pages 1-8, September.
    7. Everistus Ibekwe & Carol Haigh & Fiona Duncan & Francis Fatoye, 2017. "Economic impact of routine opt‐out antenatal human immune deficiency virus screening: A systematic review," Journal of Clinical Nursing, John Wiley & Sons, vol. 26(23-24), pages 3832-3842, December.
    8. Warburton, Rebecca Nunn, 2005. "Patient safety -- how much is enough?," Health Policy, Elsevier, vol. 71(2), pages 223-232, February.
    9. Dixon, Padraig & Harrison, Sean & Hollingworth, William & Davies, Neil M. & Davey Smith, George, 2022. "Estimating the causal effect of liability to disease on healthcare costs using Mendelian Randomization," Economics & Human Biology, Elsevier, vol. 46(C).
    10. Yaling Yang & Lucy Abel & James Buchanan & Thomas Fanshawe & Bethany Shinkins, 2019. "Use of Decision Modelling in Economic Evaluations of Diagnostic Tests: An Appraisal and Review of Health Technology Assessments in the UK," PharmacoEconomics - Open, Springer, vol. 3(3), pages 281-291, September.
    11. Office of Health Economics, 1997. "The Pros and Cons of Modelling in Economic Evaluation," Briefing 000428, Office of Health Economics.
    12. Syed Mohiuddin, 2014. "A Systematic and Critical Review of Model-Based Economic Evaluations of Pharmacotherapeutics in Patients with Bipolar Disorder," Applied Health Economics and Health Policy, Springer, vol. 12(4), pages 359-372, August.
    13. Wagstaff, Adam & Culyer, Anthony J., 2012. "Four decades of health economics through a bibliometric lens," Journal of Health Economics, Elsevier, vol. 31(2), pages 406-439.
    14. Van Herten, Loes M. & Gunning-Shepers, Louise J., 2000. "Targets as a tool in health policy. Part II: guidelines for application," Health Policy, Elsevier, vol. 53(1), pages 13-23, August.
    15. Hossein Haji Ali Afzali & Laura Bojke & Jonathan Karnon, 2018. "Model Structuring for Economic Evaluations of New Health Technologies," PharmacoEconomics, Springer, vol. 36(11), pages 1309-1319, November.
    16. Grieve, Richard & Hutton, John & Green, Colin, 2003. "Selecting methods for the prediction of future events in cost-effectiveness models: a decision-framework and example from the cardiovascular field," Health Policy, Elsevier, vol. 64(3), pages 311-324, June.
    17. Cookson, Richard & Hutton, John, 2003. "Regulating the economic evaluation of pharmaceuticals and medical devices: a European perspective," Health Policy, Elsevier, vol. 63(2), pages 167-178, February.
    18. An Tran-Duy & Annelies Boonen & Wietske Kievit & Piet Riel & Mart Laar & Johan Severens, 2014. "Modelling Outcomes of Complex Treatment Strategies Following a Clinical Guideline for Treatment Decisions in Patients with Rheumatoid Arthritis," PharmacoEconomics, Springer, vol. 32(10), pages 1015-1028, October.
    19. Neil Hawkins & Gerry Richardson & Alex J Sutton & Nicola J Cooper & Chris Griffiths & Anne Rogers & Peter Bower, 2012. "Surrogates, meta‐analysis and cost‐effectiveness modelling: a combined analytic approach," Health Economics, John Wiley & Sons, Ltd., vol. 21(6), pages 742-756, June.
    20. Afschin Gandjour & Amiram Gafni, 2013. "Internal validation of models with several interventions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(6), pages 901-909, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:51:y:2000:i:3:p:135-147. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.